Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, Phase I/II, dose escalation research study of an investigational
product called lumiliximab, given with FDA (Food and Drug Administration) approved products
fludarabine, cyclophosphamide, and rituximab (FCR). The study duration is 17 visits over 42
months or until your disease progresses and you require additional CLL therapy. The total
duration of participation in the study will be approximately 4 years, however your disease
status will be followed indefinitely (forever).